OKUR – onkure therapeutics, inc. - class a (US:NASDAQ)
Stock Stats
News
OnKure Announces Encouraging Preliminary Safety, Tolerability, and Pharmacokinetic (PK) Data from its First-In-Human PIKture-01 Trial of OKI-219 [Yahoo! Finance]
OnKure Announces Encouraging Preliminary Safety, Tolerability, and Pharmacokinetic (PK) Data from its First-In-Human PIKture-01 Trial of OKI-219
OnKure Therapeutics (NASDAQ: OKUR) was upgraded by analysts at Leerink Partnrs to a "strong-buy" rating.
OnKure Therapeutics (NASDAQ: OKUR) is now covered by analysts at Leerink Partners. They set an "outperform" rating and a $33.00 price target on the stock.
OnKure Announces New Date for Upcoming Investor Call [Yahoo! Finance]
Form 424B3 OnKure Therapeutics,
Form 8-K OnKure Therapeutics, For: Dec 10
Form S-8 OnKure Therapeutics,
Form SC 13G/A OnKure Therapeutics, Filed by: TANG CAPITAL MANAGEMENT LLC
Form SC 13G OnKure Therapeutics, Filed by: HIGHBRIDGE CAPITAL MANAGEMENT LLC
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.